Related Experiment Video
Updated: Jan 31, 2026
06:20
Urokinase-type Plasminogen Activator-induced Mouse Back Pain Model
Published on: September 1, 2023
1.7K
[New antithrombotic drugs (excluding plasminogen activators]
1Service d'hématologie biologique, CHU de Nancy, 29, avenue du Maréchal-de-Lattre-de-Tassigny, CO no. 34, 54035 Nancy.
Archives Des Maladies Du Coeur Et Des Vaisseaux
|January 25, 2002
Summary
New antiplatelet drugs target ADP or platelet aggregation, while novel anticoagulants include saccharides and direct thrombin inhibitors. Both drug classes increase bleeding risk due to limited antidotes and diagnostic tools.
Area of Science:
- Pharmacology
- Hematology
- Biochemistry
Background:
- Novel antiplatelet agents target ADP-mediated activation or glycoprotein IIb/IIIa complex.
- New anticoagulants encompass saccharide derivatives and direct thrombin inhibitors.
Purpose of the Study:
- To review current advancements in antiplatelet and anticoagulant therapies.
- To highlight the challenges in evaluating hemostasis and managing bleeding risks.
Main Methods:
- Literature review of pharmacological agents and their mechanisms of action.
- Analysis of clinical implications and research limitations.
Main Results:
- New drugs offer targeted antithrombotic activity but increase hemorrhage risk.
- Lack of specific antidotes and reliable diagnostic tools complicates management.
- Current research trends favor dosage optimization over biological monitoring.
Conclusions:
- Balancing antithrombotic efficacy with hemostatic defense remains a significant challenge.
- Development of better diagnostic tools is crucial for safer and more effective antithrombotic therapies.
Related Concept Videos
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
228
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
228
01:28Structure-Activity Relationships and Drug Design
1.8K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.8K
01:20Antiepileptic Drugs: Potassium Channel Activators
689
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
689
02:04Co-activators and Co-repressors
8.6K
Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...
8.6K
02:26tRNA Activation
22.9K
Aminoacyl-tRNA synthetases are present in both eukaryotes and bacteria. Though eukaryotes have 20 different aminoacyl-tRNA synthetases to couple to 20 amino acids, many bacteria do not have genes for all of these aminoacyl-tRNA synthetases. Despite this, they still use all 20 amino acids to synthesize their proteins. For instance, some bacteria do not have the gene encoding the enzyme that couples glutamine with its partner tRNA. In these organisms, one enzyme adds glutamic acid to all of the...
22.9K
01:26Activation Energy
86.6K
Activation energy is the minimum amount of energy necessary for a chemical reaction to move forward. The higher the activation energy, the slower the rate of the reaction. However, adding heat to the reaction will increase the rate, since it causes molecules to move faster and increase the likelihood that molecules will collide. The collision and breaking of bonds represents the uphill phase of a reaction and generates the transition state. The transition state is an unstable high-energy state...
86.6K